Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P06870

UPID:
KLK1_HUMAN

ALTERNATIVE NAMES:
Kidney/pancreas/salivary gland kallikrein; Tissue kallikrein

ALTERNATIVE UPACC:
P06870; Q66US9; Q86U61; Q8TCV8; Q9BS53; Q9NQU4; Q9UD19; Q9UMJ1

BACKGROUND:
The protein Kallikrein-1, with alternative names such as kidney/pancreas/salivary gland kallikrein and tissue kallikrein, is integral to various biological functions. It facilitates the release of Lys-bradykinin from kininogen, a process essential for maintaining vascular homeostasis and pain modulation. Furthermore, its role in the immune response against Neisseria meningitidis highlights its importance in pathogen defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Kallikrein-1 could open doors to potential therapeutic strategies. By elucidating its functions in blood pressure control, pain management, and immune defense, Kallikrein-1 emerges as a promising target for the development of novel therapeutic agents aimed at treating cardiovascular, inflammatory, and infectious diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.